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Abstract Interleukin (IL)-6-dependent human myeloma cell 
lines (HMCL) can be reproducibly obtained from patients with 
multiple myeloma and terminal disease. The growth of some of 
these HMCL can also be supported by IL-11. We show that 
IL-11-responsive, but not -unresponsive, HMCL expressed the 
gene of human IL-11 receptor (IL-I1R) and produced an auto- 
crine IL-10. All HMCL expressed the IL-10 receptor. In addi- 
tion, IL-10 induced IL-11R gene expression and conferred IL-11 
responsiveness on unresponsive HMCL. The ability of I-IMCL to 
produce IL-10 was strictly correlated with the capacity of the 
original patient's myeloma cells to produce IL-10 or not, and with 
the presence or absence of IL-10 in the patient's plasma. 
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1. Introduction 
Interleukin (IL)-l l, initially identified as an IL-6 unrelated 
growth factor for a murine plasma cell line [I], shares several 
biological activities with IL-6, i.e. as a thrombopoietic factor 
[2], inducer of acute-phase proteins [3], competence factor for 
hematopoietic stern cells [4] and bone-resorption factor [5]. 
These shared biological activities can be explained by the acti- 
vation of the same transducer chain (gp 130 transducer) by IL-6 
and IL-11 [6]. The cloning of murine IL-11 receptor (IL-I 1R) 
cDNA indicated that IL-11 binds first to its IL-11R and that 
the IL-1 I/IL-11R complex then binds to gpl30 and induces its 
dimerization in a way similar to that of IL-6 [7]. Two eDNA 
of human IL-1 IR, one coding for a membrane receptor and the 
other one for a soluble receptor, have been recently cloned [8]. 
The other 3 gpl30-activating eytokines - leukemia inhibiting 
factor (LIF), oncostatin M (OM) and ciliary neurotrophic fac- 
tor (CNTF) involve another transducer chain, LIF receptor 
(gpl90), forming a heterodimer with gpl30 [9]. It is not pres- 
ently clear whether the human IL-II/IL-11 R complex induces 
an homodimerization f gpl30 transducer [8]. 
We and others have previously reported that IL-6 is a major 
tumor growth factor in human multiple myeloma (reviewed in 
[10]), and that IL-6-dependent human myeloma cell lines 
(HMCL) can be obtained reproducibly from patients with ter- 
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minal disease [11]. We recently found that the growth of some 
H MCL can be supported by other gp 130-activating cytokines, 
including IL-11, whereas other HMCL are only sensitive to 
IL-6 [12]. In the present report, we show that IL-11-sensitive 
(but not -unsensitive) HMCL expressed IL-l IR gene and pro- 
duced IL-10. In addition, we show that IL-10 induced IL-11R 
gene expression and conferred IL-11 responsiveness on non- 
responsive HMCL. Thus, the ability of myeloma cells to pro- 
duce IL-10 or not could be a crucial marker in distinguishing 
patients whose myeloma cells are responsive only to IL-6 from 
those whose myeloma cells may also respond to IL-11. 
2. Patients, materials and methods 
2.1. Patients 
XG HMCL were obtained from three patients with plasma-cell leu- 
kemia (XG-I, XG-4 and XG-6) and one patient with pleural effusion 
(XG-2), as previously reported [11]. Myeloma cells were harvested from 
peripheral blood or pleural fluid. At the time of cell harvesting, plasma 
or pleural fluid was filtered and stored at -20°C until use. 
22. Reagents 
Recombinant IL-6 was provided by D. Stinchcomb (Synergen, 
Boulder, CO, USA); rIL-10 and antioIL-10 IgG1 MoAb by Dr. J. 
Banchereau (Schering Plough, Dardilly, France) and Dr. J. Wijdenes 
(Diaclone, Besan~on, France); and anti-IL-11 IgG1 MoAb by Dr. K. 
Turner (Genetics Institute, Boston, MA, USA). Anti-human CD3 
MoAb, magnetic beads coupled to anti-murine IgG antibodies and 
control mouse purified IgG1 MoAb were purchased from Immunotech 
(Marseille, France). 
2.3. Preparation of culture supernatants of fresh tumor cells 
Mononuclear cells were separated on Fieoll Hypaque from periph- 
eral blood samples of patients with plasma-cell eukemia. A virtually 
pure population of myeloma cells (>98%) was obtained by removing 
adherent cells and T cells using anti-CD3 MoAbs and magnetic beads. 
These cells were cultured at 106 cells/ml in RPMI 1640 supplemented 
with 2 mM of L-glutamine and 5% fetal calf serum (FCS). After 2 days 
of culturing, culture supernatants were filtered and stored at -20°C 
until use. 
2.4. Human myeloma cell lines (HMCL) 
Four HMCL were studied: XG-1, XG-2, XG-4 and XG-6. All had 
cytoplasmic lg, expressed plasma-cell antigens (Ag) (CD38 and B-B4) 
and lacked the usual B-cell Ag (CDI9 and CD20). They were not 
infected with EBV (lack of EBNA2 Ag), and their growth was com- 
pletely dependent on addition of exogenous IL-6. Their detailed charac- 
teristics have been reported elsewhere [11]. To investigate heir respon- 
siveness to various cytokines, XG cells were washed once with culture 
medium, incubated for 5 h at 37°C in culture medium alone and washed 
again twice. The cells were then cultured at various concentrations i  
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96-well flat-bottomed microplates for 5 days with either culture tnedium 
alone or graded concentrations of various cytokines. Tritiated thymid- 
ine (2.5 pCi, 25 Ci/mM, CEA, Saclay, France) was added for the last 
8 hours of culture, and tritiated-thymidine i corporation was deter- 
mined as reported elsewhere [13]. 
2.5. 1L-IO assay by ELISA 
The concentration of IL-10 in culture supernatants and patient 
plasma was evaluated using a sensitive ELISA (1 pg/ml) developed by 
J. Wijdenes [14]. This ELISA used the BN-10 anti-IL-10 MoAb as a 
catcher and biotinylated BT-10 anti-IL-10 MoAb and peroxidase 
avidin as a tracer. 
2.6. RT-PCR analysis 
Total RNA was isolated from human myeloma cell lines by the 
guanidium-CsC1 method, cDNA was synthesized from 1 pg of total 
RNA using a reverse transcription kit (Promega, Madison, WI, USA). 
Thirty-five PCR cycles (60" at 94°C. 45" at 60°C, 60" at 72°C), fob 
lowed by a 3-rain extension at 72°C, were carried out using primers 
corresponding to nucleotides 345 364 and 621 640 of the IL-10 se- 
quence, 1141-1160 and 1423-1442 of the IL-10 receptor sequence, 
1037 1060 and 1244 1267 of the [L-I 1R sequence, (~37 and 269-300 
of I L-11 sequence and 5 24 and 242 361 of the//2 m sequence. Fifteen 
microliters of each 25-/11 PCR reaction were electrophoresed on 1.59~ 
agarose gel in TAE buffer. 
2. 7. Statistical analysis 
Results are the mean values determined on six replicates. The mean 
values were compared using a t-test from small samples. 
3. Results 
3.1. htterleukin-lO produetion hy lL- l  l-responsive myeloma c.el/ 
lines 
As previously reported, XG-I .  XG-2. XG-4 and XG-6 cells 
could not grow without addition of exogenous cytokines, and 
their growth required addition of IL-6 [11]. IL-11 also sup- 
ported the proliferation of XG-4 and XG-6 cells but not XG- 1 
and XG-2 (Fig. 1). IL-I 1-responsive XG-4 and XG-6 HMCL 
unlike IL-1 l-unresponsive XG-I and XG-2 HMCL, expressed 
IL-11R gene (Fig. 2). Actually, two cDNA for IL-11R, one 
coding for the membrane receptor and the other one coding for 
a soluble form, were recently identified [8]. Our data show that 
these 2 eDNA were detected in the myeloma cell lines (Fig. 2). 
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Fig. 1. Response of XG myeloma cells to IL-I 1. Ten thousand XG 
myeloma cells were cultured for 5 days in 150,ul RPMI 1640 cell culture 
medium and 10% FCS with various IL-11 concentrations. Results are 
means _+ S.D. of tritiated thymidine incorporation determined in six 
separate culture wells. 
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Fig. 2.1L-I l receptor gene expression in XG myeloma cells. RNA was 
isolated from XG cells harvested uring exponential growth in the 
presence of I ng/ml of IL-6 (lanes XG-1, XG-2, XG-4, XG-6). In some 
experiments, l0 ng/ml of IL-10 was added for 12 h during exponential 
growth of XG-I or XG-2 cells with 1 ng/ml of IL-6 and RNA was 
extracted (lanes XG-I + IL-10 and XG-2 + IL-10). cDNA were ob- 
tained using reverse transcription and PCR were performed as de- 
scribed in section 2. Results are the bands visualized by ethidium bro- 
mide obtained with primers for IL-11R. 
The 2 IL-11-responsive XG-4 and XG-6 HMCL also produced 
IL-10, as indicated in Fig. 3 which shows the presence of IL-10 
mRNA by RT-PCR analysis in XG-4 and XG-6 cells but not 
in XG-1 and XG-2 cells. IL-10 protein was also detected in 
culture supernatants of XG-4 and XG-6 cells but not in those 
of XG-I  and XG-2 cells (Table 1). RT-PCR revealed the pres- 
ence of IL-10 receptor mRNA in the 4 HMCL (Fig. 3). No 
IL-I 1 mRNA could be detected in the 4 HMCL by RT-PCR 
(results not shown). 
3.2. lnterleukin-lO induces 1L-I I responsiveness in unresponsive 
cell lines 
XG-I  and XG-2 cells failed to proliferate with IL-11. As 
indicated in Fig. 2, 1L-10 was able to induce IL-11R gene 
expression in XG-1 and XG-2 cells. Moreover, in the presence 
of IL-10, IL-11 induced the proliferation of both HMCL in a 
concentration-dependent fashion. Maximal induction of IL-11 
responsiveness was found with 10 ng/ml of IL-10. IL-10 induc- 
tion of IL-11 responsiveness in XG-I  and XG-2 cells was inhib- 
ited by anti-lL-10 or anti-IL-11 antibodies (Fig. 4A and B). 
As shown in Fig. 1 and Table 1, autocrine IL-10-producing 
XG-4 and XG-6 HMCL spontaneously responded to IL-11. 
Addition of exogenous 1L-10, even at a high concentration (100 
ng/ml), did not increase their sensitivity to IL-11, and addition 
of a neutralizing antibody to IL-10 failed to block the IL-11 
responsiveness of these 2 HMCL (results not shown). 
3.3. IL-IO may be involved in myeloma disease in vivo 
IL-10 was detected in 2-day culture supernatants of purified 
primary tumor cells freshly explanted from XG-4 and XG-6 
patients with plasma-cell leukemia (Table 1). IL-10 was also 
l\~und in the plasma samples of these 2 patients. Conversely, 
no [L-10 was detected in culture supernatants of primary 
tumor cells or in plasma samples from XG-1 and XG-2 patients 
(Table 1 ). 
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Table 1 
IL-10 activity* in culture supernatants of myeloma cells 
XG-1 XG-2 XG-4 XG-6 
IL-10 activity in culture 
supernatant of HMCL 0 0 12 275 
IL-10 activity in culture 
supernatant of patients" 
freshly expanted 
myeloma cells 0 0 l I 1 227 
IL-10 activity in plasma of 
XG myeloma patients 0 0 110 480 
*IL-10 activity: (pg/ml). 
XG cells (3 x l0 t cells/ml) were cultured t\~r 2 days with I ng/ml of IL-6. 
and culture supernatants were then harvested. Fresh myeloma cells 
from XG patients with plasma-cell eukemia or pleural effusion were 
harvested and purified. Purified myeloma cells (>98%) were cultured 
for 2 days at 106 cells/ml in RPMI 1640 and 10% fetal calf serum. The 
culture supernatants were frozen. Plasma from XG patients was har- 
vested and frozen at the time cell lines were obtained. 
4. Discussion 
We showed that the IL-11 responsiveness of human myeloma 
cell lines was associated with their ability to express IL-I 1R 
gene and produce an autocrine IL-10, as assayed by RT-PCR 
and an ELISA. We also showed that exogenous IL-10 induced 
IL-11R gene expression and IL-11 responsiveness in myeloma 
cells initially unresponsive to IL - l l  and unable to produce 
IL-10, These findings may explain why some myeloma cell lines 
which produce an autocrine IL-10 respond spontaneously to 
IL-I 1. As the biological activity of an autocrine IL-10 is diffi- 
cult to inhibit, it is hardly surprising that no inhibit ion of Ik-I  1 
responsiveness was found when an anti-IL-10 mAb was used 
on IL-10-producing cell lines (results not shown). 
The ability of some HMCL to produce an autocrine lk-10 
was associated with IL-10 product ion by the patient's purified 
primary tumor cells and the presence of circulating IL-10 in 
plasma. This suggests that the ability of primary myeloma cells 
to produce IL-10 could be useful in identifying patients whose 
tumor cells are sensitive only to Ik-6 in vivo or to IL-6 and 
IL-11. This might be important for IL-10-producing patients 
since IL-11 is a bone cytokine produced by osteoblast cells [l]. 
and myeloma cells preferentially proliferate close to bone tis- 
sue. 
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Fig. 3. IL-10 and IL-10 receptor gene expression i  XG myeloma cell 
lines. RNA was isolated from cells harvested during exponential growth 
in the presence of I L-6. cDNA was obtained using reverse transcription. 
The different PCR were performed on the same cDNA, as described 
in section 2. Results are the bands visualized by ethidium bromide 
obtained with primers for IL-10, IL-10R or fl2m 
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Fig. 4. I L- l0 induces IL-11 responsiveness in XG-1 and XG-2 cell lines. 
Ten thousand XG myeloma cells were cultured for 5 days in 150/A 
RPMI 1640 cell culture medium and 10% FCS together with various 
lk-11 concentrations and with 10 ng/ml of IL-10 and 20 ug/ml of a 
control murine IgGl MoAb in the IL-I l + IL-10 group (m), or 10 ng/ml 
of Ik-10 and 20 ,ug/ml of an anti-IL-10 IgGl MoAb in the IL-11 + IL- 
l0 + anti-lL-10 group (e), or 10 ng/ml of IL-10 and 20/.*g/ml of an anti 
IL-I 1 lgG 1 M oAb in the !L-11 + I L-10 + anti-IL-11 group (A). Results 
are means _+ S.D. of tritiated thymidine incorporation determined in six 
separate culture wells. 
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